A retrospective study of the prescribing and outcomes of tyrosine kinase inhibitors in chronic myeloid leukaemia over a period of more than 10 years.
Fiche publication
Date publication
août 2015
Journal
Journal of clinical pharmacy and therapeutics
Auteurs
Membres identifiés du Cancéropôle Est :
Dr MOUNIER Morgane, Dr CHRETIEN Marie-Lorraine
Tous les auteurs :
Lang AS, Mounier M, Roques M, Chretien ML, Boulin M
Lien Pubmed
Résumé
Since their introduction, tyrosine kinase inhibitors (TKIs) have been increasingly used in clinical practice. We describe the prescribing and the clinical and biological consequences of two such inhibitors, imatinib and erlotinib, in patients with chronic myeloid leukaemia (CML) in a practice setting over a period of more than 10 years.
Mots clés
Adolescent, Adult, Aged, Aged, 80 and over, Antineoplastic Agents, adverse effects, Erlotinib Hydrochloride, adverse effects, Female, Follow-Up Studies, Hospitals, University, Humans, Imatinib Mesylate, adverse effects, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, drug therapy, Male, Middle Aged, Practice Patterns, Physicians', Protein Kinase Inhibitors, adverse effects, Retrospective Studies, Treatment Outcome, Young Adult
Référence
J Clin Pharm Ther. 2015 Aug;40(4):391-7